Miracor concludes financing round E with 24 million Euros

After receiving EU approval for its minimally-invasive PiCSO system a few weeks ago, Belgium-based Miracor Medical SA is encouraged by the successful, fifth round of financing. The 24 million euros in capital raised will be devoted to further development and international marketing of the breakthrough PiCSO system. The US FDA recently identified PiCSO with its ‘breakthrough designation’. The firm managed to recruit James Hallums, an internationally experienced expert, as its Vice President Sales & Marketing. He will plan and coordinate the planned launch of PiCSO in the second quarter of 2021. Read the press release on the subject (in English) here: https://t1p.de/b87u